文献速递泌尿生殖腹部MR

评价T1与T2定量成像无创评估膀胱癌HER2及PD-L1表达状态

Evaluation of T1 and T2 mapping for non-invasive assessment of HER2 and PD-L1 expression in bladder cancer.
PubMed 文献 · Abdom Radiol (NY) · 2026-03-09

前瞻性纳入60例膀胱癌患者,术前3-T MRI行T1与T2定量成像,从肿瘤最大层面勾画感兴趣区提取T1、T2值。HER2高表达组T1、T2值均低于HER2低表达组,联合模型AUC 0.923;PD-L1阳性组T1、T2值均低于PD-L1阴性组,联合模型AUC 0.839。作者认为T1、T2定量成像可能为无创评估膀胱癌HER2及PD-L1表达提供手段。

要点

  • HER2高表达组T1值1834.59±345.63、T2值81.85±24.22,均低于HER2低表达组。
  • PD-L1阳性组T1值1918.02±347.78、T2值82.72±25.12,均低于PD-L1阴性组。
  • T1与T2值联合模型评估HER2的AUC为0.923、评估PD-L1的AUC为0.839。

核心结论

  • 初步证据提示T1与T2定量成像可获得可重复的定量指标,可能为无创评估膀胱癌HER2及PD-L1表达提供手段。

研究设计与样本

  • 前瞻性研究,共纳入60例膀胱癌患者(男50例、女10例,平均年龄70.60±11.51岁),术前接受3-T MRI检查。
  • MRI方案包括T1定量成像与T2定量成像,两图均在数据采集后自动生成。
  • 在肿瘤最大层面沿肿瘤边缘手工勾画二维感兴趣区并提取T1、T2值。
  • HER2状态由免疫组织化学和FISH判定,PD-L1状态由CPS评分判定。
  • 采用单因素与多因素logistic回归分析,并通过ROC分析、校准与决策曲线分析评价模型表现。

关键影像表现/征象

  • HER2高表达肿瘤(n=29)的T1值为1834.59±345.63、T2值为81.85±24.22,均显著低于HER2低表达肿瘤(n=31)的T1值2401.97±609.48、T2值145.01±51.97(P<0.001)。
  • PD-L1阳性肿瘤(n=23)的T1值为1918.02±347.78、T2值为82.72±25.12,均显著低于PD-L1阴性肿瘤(n=37)的T1值2258.10±645.74、T2值134.23±54.19(T1比较P<0.05,T2比较P<0.001)。

诊断标准与关键数值

  • T1与T2值联合MRI模型评估HER2的AUC为0.923(95%CI:0.843-0.984)。
  • T1与T2值联合MRI模型评估PD-L1的AUC为0.839(95%CI:0.740-0.938)。

临床应用与阅片要点

  • 作者认为T1与T2定量成像可能为无创评估膀胱癌HER2及PD-L1表达提供手段。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: The purpose of this study is to investigate the diagnostic performance of T1 and T2 mapping for non-invasive assessment of Human epidermal growth factor receptor 2 (HER2) and programmed death-ligand 1 (PD-L1) expression status in bladder cancer.

METHODS: In this prospective study, patients with bladder cancer underwent 3-T MRI before surgery. The MRI protocol included T1 mapping and T2 mapping. Both T1 and T2 maps were inline generated after data acquisition. Free-hand 2D regions of interest were drawn around the tumor on the largest tumor section. T1 and T2 values were extracted from ROIs. HER2 and PD-L1 status were determined by immunohistochemistry and FISH or CPS scoring. Univariable and multivariable logistic regression analyses were performed. Model performance was evaluated by ROC analysis, calibration, and decision curve analysis.

RESULTS: This study included a total of 60 patients with bladder cancer (50 men, 10 women; mean age, 70.60 ± 11.51 years). HER2-high tumors (n = 29) demonstrated significantly lower T1 and T2 values compared with HER2-low tumors (n = 31) (1834.59 ± 345.63 vs. 2401.97 ± 609.48, P < 0.001; 81.85 ± 24.22 vs. 145.01 ± 51.97, P < 0.001). The combined MRI model of T1 and T2 values for HER2, achieved AUCs of 0.923 (95% CI: 0.843-0.984). PD-L1 positive tumors (n = 23) demonstrated significantly lower T1 and T2 values compared with PD-L1 negative tumors (n = 37) (1918.02 ± 347.78 vs. 2258.10 ± 645.74, P < 0.05; 82.72 ± 25.12 vs. 134.23 ± 54.19, P < 0.001). The combined MRI model of T1 and T2 values for PD-L1, achieved AUCs of 0.839 (95% CI: 0.740-0.938).

CONCLUSION: Preliminary evidence suggests that T1 and T2 mapping can yield reproducible quantitative metrics, which may offer a means to non-invasively assess HER2 and PD-L1 expression in bladder cancer.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Qin S, Luo H, Hong Y, et al. Evaluation of T1 and T2 mapping for non-invasive assessment of HER2 and PD-L1 expression in bladder cancer. Abdom Radiol (NY). 2026. PMID: 41801382. doi:10.1007/s00261-026-05390-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。